THMO (ThermoGenesis Holdings) Stock Based Compensation: $0.04 Mil (TTM As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

THMO ThermoGenesis Holdings Inc THMO
16 GF Score
Price $0.00
View Full Analysis

What is ThermoGenesis Holdings Stock Based Compensation?

ThermoGenesis Holdings THMO 16 Stock Based Compensation is $0.04 Mil as of Mar. 2024. GuruFocus rates THMO with a GF Score™ of 16/100.

ThermoGenesis Holdings's Stock Based Compensation for the three months ended in Mar. 2024 was $0.01 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04 Mil.

ThermoGenesis Holdings Stock Based Compensation Related Terms

ThermoGenesis Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ThermoGenesis Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ThermoGenesis Holdings Stock Based Compensation Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.88 2.56 0.27 0.04

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
THMO
16GF Score
ThermoGenesis Holdings Inc THMO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ThermoGenesis Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

What does a Stock Based Compensation of $0.04 Mil mean?
ThermoGenesis Holdings (THMO) has a Stock Based Compensation of $0.04 Mil as of Mar. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ThermoGenesis Holdings and its competitors.
Is ThermoGenesis Holdings' Stock Based Compensation too high?
ThermoGenesis Holdings' current Stock Based Compensation is $0.04 Mil. Overall, ThermoGenesis Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ThermoGenesis Holdings' Stock Based Compensation compare to MSIU and MOTS?
ThermoGenesis Holdings' Stock Based Compensation of $0.04 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ThermoGenesis Holdings and its competitors. ThermoGenesis Holdings's current Stock Based Compensation is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ThermoGenesis Holdings stock overvalued right now?
ThermoGenesis Holdings (THMO) has a current Stock Based Compensation of $0.04 Mil. The current Stock Based Compensation is $0.04 Mil. ThermoGenesis Holdings' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ThermoGenesis Holdings (THMO), the current Stock Based Compensation is $0.04 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ThermoGenesis Holdings Business Description

Address 2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
16GF Score

Get the complete analysis for THMO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price